Ian Christopher Scott
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ian Christopher Scott has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
E. Suzanne Cohen
AstraZeneca, Cambridge, United Kingdom
2 shared publications- Andrew Walding
AstraZeneca R&D, Cambridge, UK
1 shared publication - Beverley Isherwood
Advanced Science and Technology Laboratory AstraZeneca R&D Charnwood Loughborough
1 shared publication Caroline Sanden
Department of Experimental Medical Sciences, Lund University, Lund, Sweden
1 shared publicationChristopher Kell
AstraZeneca, Cambridge, United Kingdom
1 shared publicationColleen Kenton
Mesoscale Discovery, Washington, United States of America
1 shared publication
Latest Publications
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4072
Novel assays to measure forms of interleukin-33 in the circulation and airway mucosa
Introduction: Interleukin (IL)-33 is released from the airway epithelium and can sense the proteolytic and oxidative environment (Cohen, E.S. et al. Nat Comms 2015; 6:8327; Scott, I.C. et al. Sci Rep 2018; 8:3363). IL-33 amplifies inflammation via its receptor ST2 and is associated with type 2 immunity. IL-33 exists in reduced and oxidized forms of IL-33 but can be sequestered by soluble ST2 (sST2), however, there are no assays that distinguish forms. Inconsistencies with IL-33 detection with commercial assays might be due to the differential detection of these antigenically distinct forms. Here we describe new assays for IL-33 forms and measurements in patient samples. Methods: anti-IL-33 mAb were paired in S-plex assays (MSD) with lower limit of detection (LLOD): reduced IL-33 (~16 fg/ml), oxidized (ox) (~100 fg/ml) or IL-33/sST2 complexes (~100 fg/ml). Assays were evaluated in serum from healthy (n=20), asthmatics (n=14) and COPD patients (n=16) or nasal mucosal lining fluid (MLF) from atopics (n=6) following allergen challenge (NAC, 0-24h). Results: We detected comparable levels of IL-33/sST2 complex (~1-5 pg/ml) in serum from healthy individuals and patients. Total sST2 in serum was similar between patients but at high levels (~10-100 ng/ml). Reduced and oxIL-33 were undetected in serum. In contrast, we detected reduced and oxIL-33 in MLF from atopics with levels increased post-NAC that peaked after 1 h (20-1000 pg/ml). In comparison, PGD2 (1-3 ng/ml) peaked after 15 min and IL-5 (~25-300 pg/ml) after 3-10 h. IL-33/sST2 complexes were low in MLF. Conclusions: We have generated novel assays for detection of IL-33 forms that will provide insights into mechanisms regulating IL-33 activity.
- 28 September 2019
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 54 (suppl 63) , PA4072
Novel assays to measure forms of interleukin-33 in the circulation and airway mucosa
Introduction: Interleukin (IL)-33 is released from the airway epithelium and can sense the proteolytic and oxidative environment (Cohen, E.S. et al. Nat Comms 2015; 6:8327; Scott, I.C. et al. Sci Rep 2018; 8:3363). IL-33 amplifies inflammation via its receptor ST2 and is associated with type 2 immunity. IL-33 exists in reduced and oxidized forms of IL-33 but can be sequestered by soluble ST2 (sST2), however, there are no assays that distinguish forms. Inconsistencies with IL-33 detection with commercial assays might be due to the differential detection of these antigenically distinct forms. Here we describe new assays for IL-33 forms and measurements in patient samples. Methods: anti-IL-33 mAb were paired in S-plex assays (MSD) with lower limit of detection (LLOD): reduced IL-33 (~16 fg/ml), oxidized (ox) (~100 fg/ml) or IL-33/sST2 complexes (~100 fg/ml). Assays were evaluated in serum from healthy (n=20), asthmatics (n=14) and COPD patients (n=16) or nasal mucosal lining fluid (MLF) from atopics (n=6) following allergen challenge (NAC, 0-24h). Results: We detected comparable levels of IL-33/sST2 complex (~1-5 pg/ml) in serum from healthy individuals and patients. Total sST2 in serum was similar between patients but at high levels (~10-100 ng/ml). Reduced and oxIL-33 were undetected in serum. In contrast, we detected reduced and oxIL-33 in MLF from atopics with levels increased post-NAC that peaked after 1 h (20-1000 pg/ml). In comparison, PGD2 (1-3 ng/ml) peaked after 15 min and IL-5 (~25-300 pg/ml) after 3-10 h. IL-33/sST2 complexes were low in MLF. Conclusions: We have generated novel assays for detection of IL-33 forms that will provide insights into mechanisms regulating IL-33 activity.
- 9 October 2018
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 46 (5) , 1345-1353
New perspectives on IL-33 and IL-1 family cytokines as innate environmental sensors
Interleukin (IL)-1 family cytokines are important initiators of innate immunity and host defence; however, their uncontrolled activities can cause tissue-damaging inflammation. Consequently, IL-1 family cytokines have sophisticated regulatory mechanisms to control their activities including proteolytic processing for their activation and the deployment of soluble receptors and receptor antagonists to limit their activities. IL-33 is a promoter of type 2 immunity and allergic inflammation through its alarmin activity that can rapidly initiate local immune responses by stimulating innate immune cells following exposure to environmental insults, pathogens, or sterile injury. Recent publications have provided new insights into how the range and duration of IL-33 activity is regulated by direct sensing of host-derived and exogenous proteolytic activities as well as oxidative changes during tissue damage. Here, we discuss how this impacts our understanding of the roles of IL-33 in initiating immune responses and the evidence that these sensing mechanisms might regulate the activities of other IL-1 family cytokines and their biological functions. Finally, we discuss translational challenges these discoveries pose for the accurate detection of different forms of these cytokines.
- 9 October 2018
- Published by Portland Press Ltd. in Biochemical Society Transactions
- Vol. 46 (5) , 1345-1353
New perspectives on IL-33 and IL-1 family cytokines as innate environmental sensors
Interleukin (IL)-1 family cytokines are important initiators of innate immunity and host defence; however, their uncontrolled activities can cause tissue-damaging inflammation. Consequently, IL-1 family cytokines have sophisticated regulatory mechanisms to control their activities including proteolytic processing for their activation and the deployment of soluble receptors and receptor antagonists to limit their activities. IL-33 is a promoter of type 2 immunity and allergic inflammation through its alarmin activity that can rapidly initiate local immune responses by stimulating innate immune cells following exposure to environmental insults, pathogens, or sterile injury. Recent publications have provided new insights into how the range and duration of IL-33 activity is regulated by direct sensing of host-derived and exogenous proteolytic activities as well as oxidative changes during tissue damage. Here, we discuss how this impacts our understanding of the roles of IL-33 in initiating immune responses and the evidence that these sensing mechanisms might regulate the activities of other IL-1 family cytokines and their biological functions. Finally, we discuss translational challenges these discoveries pose for the accurate detection of different forms of these cytokines.
- Open Access
- 20 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-18
Interleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage
Interleukin (IL)-33 is an IL-1 family alarmin released from damaged epithelial and endothelial barriers to elicit immune responses and allergic inflammation via its receptor ST2. Serine proteases released from neutrophils, mast cells and cytotoxic lymphocytes have been proposed to process the N-terminus of IL-33 to enhance its activity. Here we report that processing of full length IL-33 can occur in mice deficient in these immune cell protease activities. We sought alternative mechanisms for the proteolytic activation of IL-33 and discovered that exogenous allergen proteases and endogenous calpains, from damaged airway epithelial cells, can process full length IL-33 and increase its alarmin activity up to ~60-fold. Processed forms of IL-33 of apparent molecular weights ~18, 20, 22 and 23 kDa, were detected in human lungs consistent with some, but not all, proposed processing sites. Furthermore, allergen proteases degraded processed forms of IL-33 after cysteine residue oxidation. We suggest that IL-33 can sense the proteolytic and oxidative microenvironment during tissue injury that facilitate its rapid activation and inactivation to regulate the duration of its alarmin function.
- 20 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-18
Open AccessInterleukin-33 is activated by allergen- and necrosis-associated proteolytic activities to regulate its alarmin activity during epithelial damage
Interleukin (IL)-33 is an IL-1 family alarmin released from damaged epithelial and endothelial barriers to elicit immune responses and allergic inflammation via its receptor ST2. Serine proteases released from neutrophils, mast cells and cytotoxic lymphocytes have been proposed to process the N-terminus of IL-33 to enhance its activity. Here we report that processing of full length IL-33 can occur in mice deficient in these immune cell protease activities. We sought alternative mechanisms for the proteolytic activation of IL-33 and discovered that exogenous allergen proteases and endogenous calpains, from damaged airway epithelial cells, can process full length IL-33 and increase its alarmin activity up to ~60-fold. Processed forms of IL-33 of apparent molecular weights ~18, 20, 22 and 23 kDa, were detected in human lungs consistent with some, but not all, proposed processing sites. Furthermore, allergen proteases degraded processed forms of IL-33 after cysteine residue oxidation. We suggest that IL-33 can sense the proteolytic and oxidative microenvironment during tissue injury that facilitate its rapid activation and inactivation to regulate the duration of its alarmin function.
- Open Access
- 24 January 2013
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 4 (2) , 157-169
Large‐scale isolation of human skeletal muscle satellite cells from post‐mortem tissue and development of quantitative assays to evaluate modulators of myogenesis
Background During aging, there is a decreased ability to maintain skeletal muscle mass and function (sarcopenia). Such changes in skeletal muscle are also co-morbidities of diseases including cancer...
- 24 January 2013
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 4 (2) , 157-169
Open AccessLarge‐scale isolation of human skeletal muscle satellite cells from post‐mortem tissue and development of quantitative assays to evaluate modulators of myogenesis
Background During aging, there is a decreased ability to maintain skeletal muscle mass and function (sarcopenia). Such changes in skeletal muscle are also co-morbidities of diseases including cancer...